ADTX News and Press, ADiTx Therapeutics Inc. From 04/02/24

A look at the top 10 most actives in the United States Trio Petroleum Corp. (TPET) rose 63.6% to $0.168949 on volume of 119,634,330 shares C3is Inc. (CISS) rose 17.5% to $0.0424 on volume of 56,452,737 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 6.6% to $3.315 on volume...

2024-04-02 08:51:10 ET More on Aditx Therapeutics, Appili Therapeutics, etc. Evofem Biosciences achieves 2023 prelim net product sales of $18.1M to $18.3M Aditxt buys Brain Scientific's portfolio of EEG brain monitoring technologies and devices Financial information ...

Assets include the FDA-approved LIKMEZ™, the ATI-1701 tularemia vaccine defense program that has been awarded a USD $14 million non-dilutive award from the DoD, and the ATI-1801 topical formulation Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX),...

2024-04-01 08:31:15 ET More on Pre-market losers & stocks. MicroStrategy Is A $1 Box Of Bitcoin Trading For $1.91 Biora Therapeutics, Inc. (BIOR) Q4 2023 Earnings Call Transcript MicroStrategy: A Bad Deal For Investors MicroStrategy among most squeezable ...

Aditxt (NASDAQ: ADTX) previously entered into a definitive agreement to acquire Evofem Biosciences Inc. (OTCQB: EVFM) , which is believed to represent a compelling opportunity to accelerate Evofem’s growth trajectory, as a subsidiary of Aditxt, into a multi-product women’s health ...

Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023 PR Newswire -- Third Consecutive Year of Phexxi Net Sales Growth -- -- Total Operating Expense Reduced 64% from 2022 Levels -- -- Sales and marketing expense as a percent...

Iochpe-Maxion S.A. ADR (IOCJY) is expected to report for quarter end 2023-12-31 The Alkaline Water Company Inc. (WTER) is expected to report for Q3 2024 Clover Leaf Capital Corp. (CLOE) is expected to report for Q4 2023 Silvergate Capital Corporation Class A (SICP) is expected to repo...

Caleres Inc. (CAL) is expected to report $0.86 for Q4 2024 B Communications Ltd (BCOMF) is expected to report for quarter end 2023-12-31 Dermata Therapeutics Inc. (DRMA) is expected to report for Q4 2023 Core & Main Inc. Class A (CNM) is expected to report $0.34 for Q4 2024 Wi...

Koninklijke KPN NV (KKPNF) is expected to report for Q4 2023 ECA Marcellus Trust I Unit (ECTM) is expected to report for Q4 2023 San Juan Basin Royalty Trust (SJT) is expected to report for Q4 2023 Avenir Wellness Solutions Inc (AVRW) is expected to report for Q4 2023 Carmell Corp...

For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy PR Newswire -- New weight loss drugs like Ozempic, Wegovy and Zepbound may make oral birth co...